Pharmacologic and Chemopreventive Strategies in Cancer Prevention

Pharmacologic and chemopreventive interventions play a crucial role in reducing cancer risk, particularly for individuals at high genetic, molecular, or environmental susceptibility. This session explores the evidence-based use of drugs and biologics to prevent the initiation, progression, or recurrence of malignancies, integrating molecular profiling, risk stratification, and clinical guidelines. Agents such as selective estrogen receptor modulators (SERMs), aromatase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), and metformin are discussed for their chemopreventive properties in breast, colorectal, and other cancers. Mechanisms of action, including modulation of hormonal pathways, inhibition of inflammatory cascades, suppression of cell proliferation, and induction of apoptosis, are examined to understand how pharmacologic interventions target early carcinogenic processes. The session emphasizes patient selection using biomarkers, genetic testing, and risk models to optimize efficacy and minimize adverse effects. Clinical trial evidence, including randomized controlled studies and long-term follow-up data, is reviewed to guide decision-making in preventive therapy. Safety monitoring, dose optimization, adherence support, and management of side effects are critical components of effective chemoprevention programs. Integration with lifestyle interventions, immunopreventive strategies, and routine screening enhances overall cancer risk reduction. Ethical considerations, including informed consent, patient autonomy, and equitable access, underpin the use of pharmacologic preventive measures. Emerging areas such as targeted small molecules, epigenetic modifiers, and combination preventive regimens are highlighted for their potential to expand personalized prevention. By combining molecular insights, clinical evidence, and individualized risk assessment, pharmacologic and chemopreventive strategies provide a proactive approach to cancer prevention, reducing incidence and improving long-term outcomes while complementing screening, immunoprevention, and lifestyle-based interventions.

    Related Conference of Pharmacologic and Chemopreventive Strategies in Cancer Prevention

    March 09-10, 2026

    13th World Machine Learning and Deep learning Conference

    Singapore City, Singapore
    March 24-25, 2026

    9th Global Congress on Spine and Spinal Disorders

    Paris, France
    March 26-27, 2026

    12th World Congress on Anesthesia and Critical Care

    Amsterdam, Netherlands
    April 15-16, 2026

    9th Annual Meeting on Diabetes and Endocrinology

    Tokyo, Japan
    April 20-21, 2026

    47th International Summit on Human Anatomy & Physiology

    Barcelona, Spain
    April 27-28, 2026

    40th International Conference on Psychiatry and Mental Health

    Amsterdam, Netherlands
    April 27-28, 2026

    37th World Congress on Neurorehabilitation

    Dubai, UAE
    May 25-26, 2026

    18th International Conference on Clinical Chemistry

    Zurich, Switzerland
    September 14-15, 2026

    6th World Medicine Congress

    Rome, Italy
    November 24-25, 2026

    6th International Conference on Medical Research and Development

    Amsterdam, Netherlands
    November 25-26, 2026

    22nd World Summit on Blockchain Technology

    Amsterdam, Netherlands

    Pharmacologic and Chemopreventive Strategies in Cancer Prevention Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in